This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

开始日期2025-09-17

申办/合作机构

Pfizer Inc.

NCT06999252

/ Not yet recruiting临床2期IIT

The Combination of Rimegepant and PD-1 Inhibitor in the Treatment of Liver Metastasis Colorectal Cancer

The goal of this clinical trial is to learn about efficacy of Rimegepant in combination with PD-1 in patients with liver metastasis colorectal cancer. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups.

开始日期2025-07-01

申办/合作机构

复旦大学

NCT06985342

/ Recruiting临床4期IIT

A Prospective, Open-Label Study Examining the Use of Rimegepant ODT 75 mg or Zavegepant Nasal Spray 10 mg for Acute Treatment of Migraine in the Emergency Department Setting

This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting.
This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.

开始日期2025-06-05

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+1]

100 项与硫酸瑞美吉泮相关的临床结果

登录后查看更多信息

100 项与硫酸瑞美吉泮相关的转化医学

登录后查看更多信息

100 项与硫酸瑞美吉泮相关的专利（医药）

登录后查看更多信息

259

项与硫酸瑞美吉泮相关的文献（医药）

2025-09-02·Pain Management

Oral rimegepant as a preventive treatment of migraine: a plain language summary of a clinical study

Article

作者: Lipton, Richard B ; Kudrow, David ; Conway, Charles M ; Kamen, Lisa ; Croop, Robert ; Goadsby, Peter J

2025-09-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The binding mechanism of Covalent Organic Frameworks (COFs) to Calcitonin Gene-Related Peptide Receptors (CGRPRs)

Article

作者: Rezvantalab, Sima ; Dabiri, Mohammad ; Imanpour, Aylar ; Beheshtizadeh, Nima

Calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein type 1 (RAMP1) are key components of the calcitonin gene-related peptide (CGRP) receptor, which is upregulated during migraine attacks, contributing to enhanced CGRP signaling. This study aimed to investigate the binding of covalent organic framework (COFs) models to CLR/RAMP1 at the molecular level using molecular dynamics (MD) and docking simulations. To assess the efficacy and inhibitory effects of COF structures on the CLR/RAMP1 complex, two antimigraine drugs, ubrogepant and rimegepant, were used as controls. These findings substantiate the pronounced affinity of the TPE-COF, 3D-Py-COF, and 4PE-1P-COF models for interacting with CGRP, impeding its function and attenuating pain. This study demonstrates that COFs can function as direct macromolecular antagonists of the CLR/RAMP1 complex, repositioning COFs from passive nanocarriers to direct macromolecular antagonists. Unlike prior work focused on COF-mediated drug encapsulation/release, we computationally validate that specific COFs inherently exhibit bioactive potential against CGRPR. However, further investigation is necessary to explore a broad range of COF structures that can be investigated initially at the molecular and mathematical scales. Thereafter, the selected COFs may undergo further evaluation, such as laboratory feasibility tests, in vitro or in vivo studies.

2025-09-01·HEADACHE

The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open‐label, single‐dose, parallel‐group study

Article

作者: Croop, Robert ; Matschke, Kyle ; Bhardwaj, Rajinder ; Morris, Beth ; Liu, Jing ; Bertz, Richard

Abstract:

Objective:

The objective of this study was to investigate the pharmacokinetics of rimegepant in participants with mild, moderate, or severe renal impairment compared to healthy adults with normal renal function.

Background:

Rimegepant is a calcitonin gene‐related peptide receptor antagonist approved in the United States for treatment of acute and preventive treatment of migraine.

Methods:

In this Phase 1, open‐label, four‐group, pharmacokinetic study, 36 participants were grouped by degree of renal impairment according to estimated glomerular filtration rate (eGFR): normal; mild (60–89 mL/min/1.73 m2); moderate (30–59 mL/min/1.73 m2); and severe (<30 mL/min/1.73 m2). Participants received a single 75‐mg oral rimegepant tablet to determine total and unbound plasma rimegepant concentrations using both matched and pooled control analysis. The study enrollment period began on October 17, 2017, and concluded on March 27, 2018.

Results:

For mild, moderate, and severe renal impairment groups, respectively, compared with matched control groups, total geometric least‐square mean ratios (90% confidence intervals) were 1.06 (0.75–1.52), 1.40 (0.97–2.02), and 1.04 (0.70–1.57) for area under the concentration–time curve from time zero to infinity (AUC0–inf) and 1.20 (0.75–1.92), 0.76 (0.42–1.37), and 0.90 (0.50–1.62) for maximum observed concentration (Cmax). Geometric mean ratios of unbound AUC0–inf were 1.22 (0.82–1.82), 1.84 (1.30–2.61), and 2.57 (1.86–3.56) in the mild, moderate, and severe renal impairment groups, respectively, using the pooled control group analysis. Relationships for eGFR versus total plasma concentrations and pharmacokinetic parameters showed no significant trends; however, there was a statistically significant (p < 0.05) relationship showing greater unbound rimegepant AUC0–inf and Cmax in participants with lower eGFR.

Conclusions:

Among participants with mild, moderate, or severe renal impairment, a ≤40% increase in total rimegepant exposure was observed following single‐dose 75‐mg administration. Unbound rimegepant AUC0–inf exposure increased 1.8‐ and 2.6‐fold in participants with moderate and severe renal impairment, respectively. The pharmacokinetic results from this study and safety data from other clinical studies were used to support rimegepant dosing recommendations in patients with renal impairment. Rimegepant has not been studied in patients with end‐stage renal disease or in patients on dialysis and should be avoided in those populations.

233

项与硫酸瑞美吉泮相关的新闻（医药）

2025-08-29

·EINPresswire

July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

2025-08-29

·EndPoints

AbbVie's Gilgamesh deal highlights pharma's one-asset mind

As the markets have tightened, biopharma companies have gotten creative with their dealmaking structures in recent years. One route — the single-asset deal — has become popular in 2025. Eli Lilly , Sanofi , GSK and AbbVie have all taken the approach this year, with AbbVie’s acquisition of a psychedelic compound from its existing partner Gilgamesh Pharmaceuticals as the latest example. Some of the single-asset deals include a “spin-co” model, with Pfizer’s Biohaven deal in 2022 setting the blueprint, and more companies have followed suit in 2025, like Scorpion Therapeutics’ deal with Lilly in January. Pfizer paid $11.6 billion for Biohaven, but mainly wanted just the approved migraine drug Nurtec ODT. So the New York pharma giant spun out the bulk of the pipeline into a new company that retained the Biohaven name. Today, Biohaven has about a dozen drug candidates across obesity, epilepsy, depression, cancer and other I&I conditions. Industry experts told Endpoints News they believe the single-asset acquisition and the spin-co model will continue to be attractive, even though these two approaches represent only a sliver of the 30-plus M&A deals in the drug development industry that have been announced so far this year. “It just makes sense,” Raymond James banker Brian Gleason said in an email. “The vast majority of acquisitions, particularly small to midsize, are entirely driven by one lead asset, independent of the target’s pipeline away from that lead. The additional pipeline assets aren’t part of the valuation and often their path forward, if included as part of the acquisition, is unclear.” Many acquisitions start as discussions around collaborations, licensing deals or some other form of partnership. In the end, value is typically ascribed to the lead program. But biotech companies with multiple assets and/or a platform that can be applied to many areas will want to continue developing it; they don’t want it to get lost in the shuffle of a major pharma’s R&D engine. “Gilgamesh was still founder-led, and they as a team have a lot more work to do. And that’s why this structure in particular for them was really exciting, because AbbVie was most interested in the single product,” said Hannah England, a life sciences partner on the Ropes & Gray legal team. They advised Gilgamesh on its deal to sell the Phase 2-stage bretisilocin to AbbVie for up to $1.2 billion, which was announced this week. England’s colleague, Matt Byron, said deal shapes are quite fluid until inked. “I’ve seen these discussions start one way and the structure change four or five times over the course of the deal lifecycle,” Byron said in a joint interview. Sometimes, companies go into the discussions with a clear picture in mind. Dren Bio made a “ deliberate decision” to “pursue a single-asset acquisition deal,” CBO Amit Mehta said in an email. The biotech sold a B cell-depleting antibody to Sanofi this spring for $600 million upfront. More could come Dren’s way via biobucks. The California startup also did the collaboration route in the past with Novartis and a licensing pact with Pfizer . “Sanofi’s focus is on acquiring specific assets and technologies that align with its strategic goals,” a spokesperson for the French pharma company said in an emailed statement. “Acquiring the entire company was not necessary to achieve these objectives.” As for Scorpion’s spin-co pact with Lilly, it sold to the Indianapolis drugmaker for up to $2.5 billion , but Lilly’s eyes were mainly on a PI3Kα inhibitor. The rest of the pipeline got spun out into a new company called Antares Therapeutics, which has already fueled up with $177 million. Adam Friedman led Scorpion and continued as CEO of the spin-co. He previously told Endpoints the spin-co model was appealing because it allowed shareholders to get money rather than betting that all parts of a licensing pact would fully come to fruition. It also allowed for most of the Scorpion team to keep working on the rest of the pipeline. Scorpion had been “very close” to an IPO but went with the M&A deal instead, he previously said. Boston Pharma, meanwhile, was also considering an IPO while entertaining pharma discussions, said Sophie Kornowski, who was CEO of the drug developer when it sold to GSK earlier this year for $1.2 billion . GSK also did a single-asset acquisition of a T cell engager from China-based Chimagen last year . Boston Pharma once had a bustling roster of 20 assets, but whittled it down to focus on a MASH drug — and that’s what GSK bought. Other assets, including a liver cancer asset, are in discussions for moving on elsewhere, Kornowski said, adding that the assets were placed in separate C corporations. An M&A deal is never guaranteed, though, and biotech management teams must chug along while going through deal discussions. “You always have to think you need to be independent. At the end, you are working towards having the best-in-class and best-in-disease drug in development and eventually be ready to market it yourself,” Kornowski said. “This is the only way for you to keep the timelines and not lower your target profile over time. You need to set up a high bar and stick to it, which is incredibly difficult.” If the capital markets thaw, Byron said the industry “might see that take away from some of the momentum for” single-asset and spin-co deals, but these deal structures will likely continue intriguing both the buy-side and sell-side.

并购临床1期IPO引进/卖出

2025-08-26

·学术经纬

致敬时代丨致残率高却总被忽视，“偷走”超10亿人的人生，新药研发如何令患者重获新生？

编者按：2025年，药明康德迎来创立25周年的重要里程碑。值此契机，我们向所有与我们共同书写产业变革篇章的科学家、医药人和投资者致以衷心感谢与诚挚敬意，也特别推出“致敬时代”系列，回顾全球同仁如何借助科学与合作的力量，不断拓展治疗边界、改善患者命运。四分之一个世纪的坚守，只为加速每一款新药的诞生。下一个25年，我们将继续心怀感恩与敬畏，依托独特的CRDMO模式，与全球伙伴携手同行，共赴健康未来。偏头痛影响着全球超10亿人。这是一种严重的神经系统疾病，患者在疾病发作时十分痛苦，症状包括剧烈的搏动性反复头痛，恶心呕吐、头晕、对声光触觉气味极度敏感等，部分患者甚至会在这种痛苦症状中度过数日。长期发作和对复发的恐惧，还导致大量患者出现抑郁、焦虑和睡眠障碍，严重者达到致残级别。根据2019年全球疾病负担研究（GBD2019）数据，偏头痛是全球第二大致残性疾病，在年轻女性（15~49岁）中更是致残的首要原因。近几十年来，偏头痛治疗领域迎来重大突破，尤其是降钙素基因相关肽（CGRP）类药物的出现，开启了偏头痛治疗的新纪元，更为无数患者带来“新生”。作为全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，药明康德在25年发展历程中，见证了CGRP类药物从实验室到临床的突破历程，更通过提供一体化、端到端的新药研发和生产服务，助力全球合作伙伴加速包括偏头痛在内的创新疗法的上市进程，造福病患。今天这篇文章将再次回望科学家攻坚偏头痛的历程，向为这一领域付出努力和心血的所有人致敬。图片来源：123RF 从疾病发现，到曲折反复的科学探索偏头痛最早的记载可追溯至公元前3000年左右的美索不达米亚诗歌中，当时其“带有抽疼感的头痛”的特征已被捕捉。可惜科学的曙光却迟迟未至，在之后漫长的时光长河里，人类对其本质的探索一度踟蹰不前。直到17世纪，血管学假说和神经源假说相继被提出，才开启了人们对偏头痛的科学认知。然而科学的进展总是曲折反复，随着研究的深入，这两种学说都遭到不同程度的挑战。此后百余年间，关于偏头痛病因的研究处于僵局，研究者们转而将精力投入到对偏头痛的治疗探索中。 18世纪中后期，麦角菌被发现具有促进血管收缩、肌肉痉挛、麻痹神经的作用。之后，麦角胺药物开始被应用于偏头痛治疗。尽管这类药物有一系列不良反应，但它们的确减少了患者的疼痛。麦角胺类药物作为血管收缩剂治疗偏头痛被率先写入英国的教科书，也使得血管学假说一度备受认可。上世纪后半叶，用于偏头痛治疗的曲坦类药物诞生。相比之下，曲坦类药物通过激活血清素（5-HT，一种血管收缩剂）受体促进血管收缩，以缓解偏头痛症状，其高选择性使其可避免一些潜在不良反应，因而成为偏头痛治疗的重要选择。上世纪70年代，还有多种用于治疗心脏病、癫痫和抑郁症的药物（如β受体阻滞剂）被意外发现能预防偏头痛。研究表明，它们通过降低大脑皮层和疼痛通路的兴奋性来起作用。后来，FDA先后批准了多种与此有关的药物用于偏头痛治疗。这些药物共同构成了偏头痛患者的治疗选择，且目前依然在偏头痛临床治疗中发挥着重要作用。但这些药物仅对部分患者起效，并伴随着一系列不良反应，患者仍然缺少一款“量身定制”的特效药物。开发新型特异性抗偏头痛药物迫在眉睫。图片来源：123RF 数十年接力，发现偏头痛关键机制问题又回到了偏头痛疾病本身——揭示偏头痛发作机制，才能为开发新疗法打开关键突破口。上世纪70年代，这一领域终于迎来重大突破。 1975年前后，来自哈佛医学院麻省总医院的Michael Moskowitz教授及其团队研究证明，偏头痛发作涉及两个关键因素的相互作用：三叉神经与脑膜及其相关血管。Moskowitz教授提出：当三叉神经纤维被激活时，会释放化学信号使脑膜血管扩张，从而引发局部炎症并最终导致剧烈头痛。他随后用“三叉神经血管系统”这一术语来描述三叉神经、脑膜血管与中枢神经系统之间的关联。但彼时尚无法明确三叉神经释放的这种“化学信号”的具体成分。几乎同一时期，来自隆德大学的Lars Edvinsson教授团队首次在颅内血管系统中检测到一种新型神经肽——血管活性肠肽，这是一种强效血管舒张剂。随后十年间，大量在脑血管神经支配中起作用的神经肽被鉴定出来，其中包括CGRP。Lars Edvinsson教授团队也进一步研究证实，三叉神经节中超半数神经元含有CGRP，并提出“CGRP参与偏头痛发作病理生理过程”的假说。这一假说在他与当时在澳大利亚亨利王子医院（Prince Henry Hospital）神经内科工作的Peter Goadsby博士开展的合作研究中获得了确证。1990~1994年间，他们合作研究发现：CGRP是三叉神经痛通路中的一个关键递质，在偏头痛发作时选择性释放。他们的研究首次证实，CGRP在偏头痛中起着至关重要的作用，这为后来治疗偏头痛的CGRP拮抗剂类药物的出现奠定了基础。此外，1990年前后，更多研究者的发现也陆续为偏头痛的机制和治疗提供更多的佐证。比如，英国药理学家Patrick Humphrey博士发现的5-HT受体激动剂舒马曲坦可阻断CGRP从三叉神经节释放的过程，为这类曲坦类药物能够治疗偏头痛提供了更多的证据。来自哥本哈根大学的Jes Olesen教授及其团队为CGRP从实验室走向临床补上最后一环，他们通过实验证明：外源性CGRP可诱发偏头痛患者发作，确立了CGRP在触发偏头痛中的因果关系，随后进一步证实CGRP阻断剂能有效治疗偏头痛。目前已经知道，CGRP是由37个氨基酸组成的神经肽，存在于神经系统中，是一种强效的血管舒张剂和脑血管痛觉调节物质。使用CGRP靶向药物阻断CGRP或其受体，可用于减轻偏头痛的症状。图片来源：The Brain Prize官网正是这些神经学家的共同努力，奠定了CGRP在偏头痛中的临床研究基础。此后数年，这些基础研究突破激发了业界对CGRP靶向药物的研发热情，也开启了偏头痛研究与治疗的新纪元。自2018年起，FDA陆续批准了多款CGRP靶向药物，创新疗法的到来显著改善了众多患者的生活质量。在有公开记载的治疗案例中，大量偏头痛患者认为这类药物令他们“重获新生”。 2021年，素有“神经科学领域的诺贝尔奖”之称的“The Brain Prize”（大脑奖）将荣誉授予了Lars Edvinsson教授、Peter Goadsby教授、Michael Moskowitz教授和Jes Olesen教授。颁奖词中写道，他们关于偏头痛的研究完美诠释了“从临床到实验室再回归临床”的转化医学范式，且已产生切实的临床效益。靶向药物诞生，偏头痛治疗迎来新变革 CGRP通路的发现和验证，使得偏头痛疗法的开发进入了新阶段。2004年初，《新英格兰医学杂志》发表了一项CGRP受体拮抗剂BIBN 4096 BS治疗急性偏头痛的临床研究结果。公开资料显示，这是最早进入临床开发阶段的CGRP拮抗剂类药物之一。此后，多款CGRP靶向小分子和抗体类药物陆续进入临床。相比于小分子CGRP靶向疗法，CGRP靶向抗体疗法更早实现获批上市突破。2018年5月，安进（Amgen）旨在阻断CGRP受体的单抗药物erenumab成为FDA批准的首款治疗成人偏头痛的预防性治疗药物。之后的两年内，又有3款CGRP类单抗疗法接连获批，分别是梯瓦（Teva）的fremanezumab、礼来（Eli Lilly and Company）的galcanezumab和丹麦灵北（Lundbeck）的eptinezumab。由于较长的半衰期，抗体药物可以实现每月甚至每三个月一次给药，作为偏头痛的预防性治疗手段，在降低偏头痛发作频率和减少头痛天数方面疗效显著。小分子CGRP受体拮抗剂的研发历程历经曲折，也很快取得突破。在首代化合物因长期用药下的肝脏不良反应问题而研发受阻后，经结构修饰与优化后的第二代化合物成功克服了这一缺陷，其安全性得到了显著提升。2019年，FDA批准了艾尔建（Allergan，现在已被艾伯维[AbbVie]收购）公司的小分子CGRP受体拮抗剂ubrogepant用于治疗急性偏头痛，为患者带来口服治疗选择。两年后，艾伯维另一款口服CGRP受体拮抗剂atogepant也获FDA批准，用于成人发作性偏头痛预防性治疗，并在2023年再次获批用于预防性治疗成人慢性偏头痛。与此同时，研发人员也在进一步优化这类药物的用药方式。比如辉瑞（Pfizer）通过收购Biohaven所获得的rimegepant于2020年获批，成为首款获FDA批准的拥有快速口腔崩解片剂型的CGRP受体小分子拮抗剂，它能够让患者在1小时内恢复正常功能。同样来自辉瑞的zavegepant，于2023年成为FDA批准的用于急性治疗偏头痛成人患者的首款CGRP受体拮抗剂鼻内喷剂，它可在15分钟内快速起效。图片来源：123RF 除CGRP靶向药物外，研究人员仍在不断深入探索偏头痛的更多发病机制。例如，曲坦类药物后来被发现可以通过抑制由三叉神经激活诱导的CGRP释放，从而缓解偏头痛。2019年，Dr. Reddy’s Laboratories和其下属公司Promius Pharma开发的曲坦类药物舒马曲坦的鼻喷雾剂sumatriptan获FDA批准用于急性偏头痛治疗，该创新剂型可加速药物吸收，迅速缓解疼痛。同年获FDA批准的lasmiditan则是一种5-HT1F受体激动剂，作为首个获FDA批准的“地坦”（ditans）类药物，与作用于5-HT1B/1D受体的曲坦类药物不同，它不会激活5-HT1B受体，无血管收缩作用，因此对伴有心血管疾病的偏头痛患者来说更为安全。目前，还有多个新兴靶点陆续被发现具有偏头痛治疗或预防潜力，部分相关产品已经进入临床研究。例如钙离子通道TRPM3，其参与神经炎性疼痛信号传递；引发偏头痛的潜在介质PACAP，其水平上升可诱发偏头痛发作；以及GABAA受体，研究表明调节其抑制作用可能对偏头痛治疗具有积极影响等。坚持创新和合作，继续为驱散疾病阴霾砥砺前行从古代扑朔迷离的“抽疼感”，到上世纪90年代CGRP被确定为偏头痛治疗靶点，从2000年世纪之交开启CGRP类药物的研发，到如今多款靶向药物获批造福患者，人类对抗偏头痛的征程已经走过了漫长的道路，并取得了突破性的成果。不过，当下人们与偏头痛这一“紧箍咒”的较量仍将继续。CGRP靶向药物等现有药物仍然不能完全治愈偏头痛，现有研究也未能完整阐明偏头痛患者在头痛前出现神经性先兆等独特症状，这一领域仍然存在未解之谜和未满足的医疗需求，等待科研人员去突破。作为医药创新的赋能者，药明康德也一如既往地通过一体化、端到端的CRDMO研发平台，提供从早期药物发现和研究、开发到商业化生产的全面服务，助力全球合作伙伴加速包括偏头痛在内的各类神经系统疾病创新疗法的研发进程，让更多突破性的疗法造福患者。例如在偏头痛/疼痛领域，CGRP受体属于G蛋白偶联受体（GPCR）家族，后者是哺乳动物中最大的膜蛋白家族，也是药物开发的重要靶点。公开信息显示，药明康德生物学业务平台拥有丰富的GPCR蛋白生产经验，突破了难以获取稳定、纯净且均质的膜蛋白的瓶颈，也给后续结晶和冷冻电镜样品制备铺平了道路。该平台拥有超过15年的结构生物学样品制备与结构解析经验，为靶向GPCR的药物研发提供了强有力的支持。药明康德生物学业务平台还建立了多种临床前疼痛模型，能够满足急性与慢性炎症性疼痛、术后疼痛、急性伤害性感受、慢性神经性疼痛、纤维肌痛样疼痛和骨关节炎等领域的各种药物研发需求，为全球合作伙伴提供多样化、一体化的疼痛模型服务，助力开发包括CGRP靶点在内的各种治疗药物。在这场人类与偏头痛的漫长博弈中，我们相信科学创新的光芒，以及合作的力量终将驱散疼痛的阴霾。药明康德也期待与业界的各位同仁一道携手共进，早日为更多的患者缓解病痛，带来更多“生”的希望。参考资料： [1] The BRAIN PRIZE官网. Retrieved August 20, 2025, from https://brainprize.org/winners/migraine-2021 [2] Olesen et al. (2004) Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine.The New England Journal of Medicine. Doi:10.1056/NEJMoa030505 [3] Paemeleire, et al. (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet.doi: 10.1016/S0140-6736(25)00109-6. [4] Steiner et al. (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain, doi: https://doi.org/10.1186/s10194-020-01208-0 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

100 项与硫酸瑞美吉泮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫酸瑞美吉泮	N02C	DB12457

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性偏头痛	韩国	Pfizer Pharmaceuticals Korea Ltd.	2025-03-24
偏头痛	美国	Pfizer Inc.	2020-02-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
无先兆偏头痛	临床3期	美国	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	中国	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	日本	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	加拿大	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	韩国	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	英国	Pfizer Inc.	2025-03-11
颞下颌关节障碍	临床3期	美国	Pfizer Inc.	2022-05-05
无鼻息肉的慢性鼻窦炎	临床3期	美国	Pfizer Inc.	2022-02-17
鼻息肉	临床3期	美国	Pfizer Inc.	2022-02-17
先兆偏头痛	临床3期	美国	Pfizer Inc.	2021-04-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05207865 (CTgov)	临床4期	偏头痛 \| 畏光	441	Rimegepant	繭餘壓遞衊醖網鬱夢艱 = 淵淵憲選鹽遞艱範顧窪鑰淵鹽壓遞築糧夢鏇醖 (願憲鹹獵範簾鑰淵積襯, 淵蓋鏇鬱鬱廠獵鹹壓窪 ~ 網鹹憲餘觸顧鑰顧膚壓) 更多	-	2025-09-03
NCT04629950 (CTgov)	临床2期	斑块状银屑病	41	Rimegepant (Rimegepant)	顧鹹鏇簾壓鏇獵憲範鏇(蓋鹹衊鹽鬱艱衊選積鏇) = 襯壓遞遞糧鏇鏇襯遞觸壓淵夢齋窪衊憲築簾製 (壓鬱鹽願衊鹹願艱顧構, 34.43) 更多	-	2025-07-17
				Placebo (Placebo)	顧鹹鏇簾壓鏇獵憲範鏇(蓋鹹衊鹽鬱艱衊選積鏇) = 遞淵窪醖廠鬱築鹹淵餘壓淵夢齋窪衊憲築簾製 (壓鬱鹽願衊鹹願艱顧構, 32.58) 更多
NCT05399485 (CTgov)	临床3期	偏头痛	496	Rimegepant (Rimegepant)	願網襯網艱範簾廠鏇獵(繭糧鏇鑰願鏇蓋膚鹹鑰) = 繭艱積選遞艱簾壓醖繭廠繭糧遞醖糧齋窪淵簾 (壓鏇鑰憲鏇窪廠廠積壓, 夢衊遞鏇壓壓餘餘願願 ~ 願艱築範鑰衊壓醖壓壓) 更多	-	2025-07-14
				Placebo (Placebo)	願網襯網艱範簾廠鏇獵(繭糧鏇鑰願鏇蓋膚鹹鑰) = 積範鏇窪窪衊鑰觸遞衊廠繭糧遞醖糧齋窪淵簾 (壓鏇鑰憲鏇窪廠廠積壓, 顧願憲鹽衊製衊範鬱構 ~ 蓋製廠壓製觸構鹽衊鹽) 更多
NCT03266588 (Pubmed \| Cephalalgia)	临床2/3期	-	-	Triptan-naïve participants	繭鹽淵壓願壓鹹鏇網鹽(網壓窪顧繭窪積製製廠) = 繭獵願鬱選齋鹽夢製鹽鹽憲夢糧鑰壓構獵觸艱 (顧醖製獵遞糧鹽壓鹽窪 ) 更多	积极	2025-07-01
				Triptan-using participants	繭鹽淵壓願壓鹹鏇網鹽(網壓窪顧繭窪積製製廠) = 顧鏇遞膚鏇遞蓋範齋餘鹽憲夢糧鑰壓構獵觸艱 (顧醖製獵遞糧鹽壓鹽窪 ) 更多
NCT05399459 (Pubmed \| Headache)	临床2/3期	偏头痛	706	Rimegepant 25 mg	鑰築齋積鹹鬱夢簾築壓(選窪壓鏇衊醖築餘蓋壓) = 齋築範憲願願鑰積壓餘淵糧餘醖憲願淵夢壓遞 (獵淵鑰鑰製顧遞廠餘選 )	积极	2025-06-30
				Rimegepant 75 mg	鑰築齋積鹹鬱夢簾築壓(選窪壓鏇衊醖築餘蓋壓) = 鏇鹽蓋醖顧夢顧鏇繭衊淵糧餘醖憲願淵夢壓遞 (獵淵鑰鑰製顧遞廠餘選 )
NCT03732638 (Pubmed \| Headache)	临床2/3期	偏头痛	603	Rimegepant 75 mg EOD	觸繭築範糧齋窪網齋觸(繭齋簾膚製簾艱顧淵觸) = n = 4, 0.7% 繭範齋鑰遞製壓製壓網 (網鬱齋膚襯構夢壓構鬱 ) 更多	积极	2025-06-30
NCT05399485 (Pubmed \| Headache)	临床3期	偏头痛	484	Rimegepant 75 mg	鏇憲鏇製觸淵築餘網獵(遞窪襯醖壓積鹹艱簾壓) = 選膚築窪範糧鑰鹹憲築鹹遞觸餘襯膚簾願遞壓 (衊壓鹹遞鏇鹹願鹽齋衊, -1.73 ~ -0.38)	积极	2025-06-20
P1-12.008 (AAN2025)	N/A	偏头痛	-	Rimegepant users	網鏇繭鬱膚遞餘鏇鏇淵(淵衊觸製艱鬱築醖築齋) = 淵憲鬱膚鏇選繭蓋構餘艱糧遞範簾鹽糧蓋齋遞 (憲鬱顧選願餘構築憲窪 ) 更多	积极	2025-04-07
				Triptan users	網鏇繭鬱膚遞餘鏇鏇淵(淵衊觸製艱鬱築醖築齋) = 蓋衊顧淵鹹構艱鏇鏇範艱糧遞範簾鹽糧蓋齋遞 (憲鬱顧選願餘構築憲窪 ) 更多
NCT05399459 (P8-12.006, AAN2025)	临床2/3期	偏头痛	706	Rimegepant 25 mg	網獵餘襯壓顧範壓鑰製(壓獵醖艱衊鹹膚獵衊範) = 憲製鏇膚鹹簾範艱鬱繭築壓選顧製觸壓襯廠憲 (淵憲壓齋積網艱願築顧 ) 更多	积极	2025-04-07
				Rimegepant 75 mg	網獵餘襯壓顧範壓鑰製(壓獵醖艱衊鹹膚獵衊範) = 鑰憲憲繭獵遞鬱鏇衊廠築壓選顧製觸壓襯廠憲 (淵憲壓齋積網艱願築顧 ) 更多
NCT05248997 (CTgov)	临床3期	鼻息肉 \| 无鼻息肉的慢性鼻窦炎	261	Rimegepant (Rimegepant 75 mg)	襯憲觸遞築淵構膚醖鹹(鹽網淵糧衊夢繭糧範鹽) = 窪蓋淵廠鏇鹹窪繭艱襯構餘衊襯襯範齋製膚鑰 (壓繭膚鹽艱繭網壓衊壓, 鹹夢構願餘鑰獵鹹鏇淵 ~ 顧蓋獵窪積選選鑰繭積) 更多	-	2025-03-26
				placebo+rimegepant (Placebo)	襯憲觸遞築淵構膚醖鹹(鹽網淵糧衊夢繭糧範鹽) = 醖觸鑰遞餘鏇鬱鏇範餘構餘衊襯襯範齋製膚鑰 (壓繭膚鹽艱繭網壓衊壓, 餘獵醖餘網衊製鑰窪窪 ~ 憲廠糧選糧齋窪範壓構) 更多